Recent News

559 News Items found
By switching from one cellular identity to another, lung cancer cells can evade targeted therapies. MSK scientists are trying to stop that from happening.
Charles Rudin and Dana Pe'er
Stem-like cells that make up only a tiny fraction of the total cells in a lung tumor could be the key to stopping the disease’s deadly spread, say researchers at Memorial Sloan Kettering.
Justin Perry, PhD
Justin Perry, PhD, cell biologist and immunologist of Memorial Sloan Kettering’s (MSK) Sloan Kettering Institute (SKI) has been named a recipient of the 2021 National Institutes of Health (NIH) Director’s New Innovator Award.
Katharine Hsu and Rosa Sottile
Part natural killer, part T cell, this hybrid immune cell has a “double sword” for fighting cancer.
Dana Pe'er, PhD
Dana Pe’er, PhD, computational biologist and lab head at Memorial Sloan Kettering Cancer Center’s (MSK) Sloan Kettering Institute (SKI), is one of 33 biomedical researchers named a Howard Hughes Medical Institute (HHMI) investigator today.
Zhongmin Wang
Announcement
Meet Zhongmin Wang, a fifth-year doctoral student in the Gerstner Sloan Kettering Graduate School of Biomedical Sciences (GSK), who has been awarded the 2021 Chairman’s Prize.
Direna Alonso-Curbelo, PhD
Direna Alonso-Curbelo, PhD, of Memorial Sloan Kettering Cancer Center’s (MSK) Sloan Kettering Institute (SKI), has been named a winner of the 2021 Blavatnik Regional Awards for Young Scientists in the “Life Sciences” category.
Man holding an IUD
Could an implantable IUD help detect cancer early, when it is most curable? Scientists at the Sloan Kettering Institute are betting yes.
A collage of photos showing a zebrafish with GFP-labeled melanocytes, magnified GFP-labeled melanocytes, and hPSC-derived melanocytes growing in a dish.
Experiments with zebrafish and human pluripotent stem cells reveal the necessary ingredients, besides genetic mutations, that fuel the development of melanoma.
MSK scientists Margaret Callahan, Ronglai Shen, and Katherine Panageas
A blood-based test identifies patients in whom immunotherapy may ‘LAG.’